Loading…
← CockpitCompetitor Analysis › 4887.T SAWAI GROUP HOLDINGS Co., Ltd.Open in the cockpit ↗

SAWAI GROUP HOLDINGS Co., Ltd.4887.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.

≈ Japan's Viatris / TevaMomentum neutral 46
Mkt cap
$1.01B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$5.93M
20-day average traded
Fwd P/E
12.0×
forward earnings
ROIC−WACC
-0.6 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
89 days
15 Feb 2027
Close · JPY¥1,667
1D-1.2%
1W-0.7%
1M+0.8%
3M+2.1%
6M-18.0%
YTD-29.3%
1Y-9.2%
ATR %2.8%
52w lowhigh31.9% off high

What SAWAI does

One of Japan's largest generic pharmaceutical manufacturers, supplying off-patent drugs nationwide.

Sold to hospitals and pharmacies through wholesalers, with prices set on the government's reimbursement list and cut in regular revisions, so the volume of generic substitution matters more than price. Profit depends on running plants efficiently as unit prices fall.

In one line: Japan's Viatris / Teva.

Products and services

  • Generic prescription drugs
  • Contract manufacturing for other pharma

Customers

  • Hospitals
  • Pharmacies
  • Health insurers (via reimbursement)

Where it sits in the supply chain

  • Health care
  • Generic pharmaceuticals
  • Generic drug manufacturing and sales

What could go right

  • Government push for generic drug substitution

What could go wrong

  • Recurring government-mandated generic price cuts
  • Past manufacturing quality/compliance issues in the industry

Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.

Headquarters: Osaka, Japan · Founded: 1929 · Employees: 3,630

Named competitors

SAWAI at a glance

Size SAWAI (4887.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.01B, the 730th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,667 on 18 Nov 2026.

Performance Over six months the shares fell 18.0%, against -9.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 2.4% over the last twelve months (peer median +7.7%); the operating margin is 8.6% (peer median 13.2%).

Valuation It trades at 12.0× forward earnings against a peer median of 20.6× (5th cheapest of 15).

Capital Return on invested capital runs 0.6 points below its cost of capital (5.0% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 20264887.T 96Peer median 92
Six months, rebased to 100: SAWAI against the median of its 20 peers (local-currency closes).

SAWAI financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥205B¥202B¥189B¥177B¥164B
Revenue growth—+7%+7%+8%—
Gross profit¥58.6B¥58.8B¥56.4B¥54.3B¥50.3B
EBITDA¥34.5B¥36.4B¥35.5B¥36.9B¥33.2B
Net income¥9.52B¥10.4B¥12.0B¥13.7B¥12.7B
Free cash flow-¥10.0B-¥5.98B¥7.28B¥5.23B-¥7.70B
Capital expenditure¥27.8B¥24.5B¥27.5B¥24.6B¥27.1B
Total debt¥126B¥109B¥95.1B¥87.1B¥77.1B

Quarterly statements and history in the cockpit →

SAWAI competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%0006503007026880916051163004976887106885134553002737AARTIPHARMSVRA688382600129BSLNSPTXPGHLBLUEJET45654887.T6-month return →1-month return →
Up and to the right = strong over both horizons. SAWAI is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×20×40×60×0006503007026051163004976887106885134553002737600557600129BSLNPGHLBLUEJET4887.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SAWAI is the large dot.

SAWAI competitors and peer comparison

Head to head with its named competitors (4887.T vs 4553.T vs VTRS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
SAWAI 4887.T$1.01B-18%+2%9%12.0×n/a
Towa Pharmaceutical 4553.T$1.03B-10%+7%9%7.7×-0.3%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How SAWAI compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SAWAI against its 20 peers (data as of 18 Nov 2026)
Measure4887.TPeer medianRank in peer set
1-month return+0.8%-5.0%7th highest of 21
6-month return-18.0%-9.5%8th lowest of 21
Distance from 52-week high-31.9%-30.5%11th highest of 21
Revenue growth (TTM)+2.4%+7.7%7th lowest of 19
Operating margin8.6%13.2%8th lowest of 19
Forward P/E12.0×20.6×5th cheapest of 15
ROIC minus cost of capital-0.6 pp+0.5 pp8th lowest of 19
EV / EBITDA7.5×19.7×2nd cheapest of 7
Net debt / EBITDA2.8×0.5×3rd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%

Questions

Who are SAWAI's main competitors?
Named competitors: Towa Pharmaceutical (4553.T), Nichi-Iko Pharmaceutical (private or unlisted), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Renhe Pharmacy (000650.SZ), Zhejiang Tianyu Pharmaceutical (300702.SZ), Shanghai Yizhong Pharmaceutical (688091.SS), Aurisco Pharmaceutical (605116.SS), Jiangxi Fushine Pharmaceutical (300497.SZ), Shanghai InnoStar Bio-tech (688710.SS).
Is SAWAI expensive compared with its peers?
On forward p/e it trades at 12.0× against a peer median of 20.6×, 5th cheapest of 15 in its peer set.
How has SAWAI stock performed?
Over six months to 18 Nov 2026 the shares returned -18.0% against -9.5% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.